Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer.

European journal of pharmacology - 5 Nov 2018

Yang Zheng, Zhang Shao-Lin, Hu Xiaohui, Tam Kin Yip

Abstract excerpt

Although epidermal growth factor receptor (EGFR) inhibitors have been used to treat non-small cell lung cancer (NSCLC) for decades with great success in patients with EGFR mutations, acquired-resistance inevitably occurs after long-term exposure to the treatment of EGFR inhibitors. Glycolysis is a predominant process for most cancer cells to utilize glucose, which referred to as the Warburg Effect. Targeting...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Drug Synergism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Glycolysis

Share to Mice, Nude

Share to Pyruvate Dehydrogenase Acetyl-Transferring Kinase

Share to RNA, Small Interfering

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 30213498
DOI: 10.1016/j.ejphar.2018.09.016

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer.PMID 30213498Read ↗

Anti-cancer synergy of dichloroacetate and EGFR tyrosine kinase inhibitors in NSCLC cell lines.Semantic proximity Read ↗

Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer.Semantic proximity Read ↗

Mitochondrial pyruvate carrier function is negatively linked to Warburg phenotype in vitro and malignant features in esophageal squamous cell carcinomas.Semantic proximity Read ↗

Enhanced Sensitivity of Nonsmall Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors to Phenformin: The Roles of a Metabolic Shift to Oxidative Phosphorylation and Redox Balance.Semantic proximity Read ↗

Inhibition of pyruvate dehydrogenase kinase redirects NSCLC cell metabolism and counteracts development of resistance to epidermal growth factor receptor tyrosine kinase inhibitorsSemantic proximity Read ↗

PKM1 is involved in resistance to anti-cancer drugs.Semantic proximity Read ↗

Mitochondrial metabolism as a potential novel therapeutic target for lung adenocarcinomaSemantic proximity Read ↗

DRP1 promotes lactate utilization in KRAS-mutant non-small-cell lung cancer cells.Semantic proximity Read ↗

Pyruvate dehydrogenase kinase expression profile is a biomarker for cancer sensitivity to dichloroacetate-mediated growth inhibitionSemantic proximity Read ↗

Aldehyde dehydrogenase is used by cancer cells for energy metabolismSemantic proximity Read ↗

PGK1 Promotes NSCLC Progression by Enhancing Aerobic Glycolysis and Activating AKT/ERK Signaling PathwaySemantic proximity Read ↗

PGK1 promotes NSCLC progression by enhancing aerobic glycolysis and activating the AKT/ERK signaling pathwaySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.